Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

REPLIGEN CORP Director's Dealing 2017

Dec 18, 2017

30826_dirs_2017-12-18_91827a8f-918e-42fe-a76b-86ff2cbe0345.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REPLIGEN CORP (RGEN)
CIK: 0000730272
Period of Report: 2017-12-14

Reporting Person: Benjamin Howard (VP Business Development)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-12-14 Common Stock M 2646 $15.91 Acquired 36554 Direct
2017-12-14 Common Stock M 6021 $26.20 Acquired 42575 Direct
2017-12-14 Common Stock M 4062 $26.05 Acquired 46637 Direct
2017-12-14 Common Stock S 12729 $35.3394 Disposed 33908 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2017-12-14 Stock Option (Right to Buy) $15.91 M 2646 Disposed 2024-02-27 Common Stock (2646) Direct
2017-12-14 Stock Option (Right to Buy) $26.20 M 6021 Disposed 2025-02-26 Common Stock (6021) Direct
2017-12-14 Stock Option (Right to Buy) $26.05 M 4062 Disposed 2026-02-26 Common Stock (4062) Direct

Footnotes

F1: This option is currently exercisable.

F2: $35.3394 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.22 to $35.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The shares vest in equal annual installments over a three-year period beginning on the first anniversary of the grant date.